Latest Updates of Key Players in the U.S. AI in Life Science Market
| Company | Headquarters | Latest Update |
| Pfizer | United States | Pfizer developed the COVID-19 vaccine quickly, leveraging AI-based drug discovery's potential despite the low 12% success rate of drugs in clinical trials. |
| Sanofi | United States | Sanofi's digital transformation accelerates drug discovery, clinical development, and personalized patient care, reducing time to therapy. |
| Novartis & Eli Lilly | United States | Eli Lilly exclU.S.ive global license for the advancement, manufacturing, and commercialisation of new oral therapeutics in preclinical development for some indications. |
| AstraZeneca | United States | AstraZeneca is leveraging digital twins, surrogate AI-based models, and agentic AI-driven systems to speed up pharmaceutical production. |
| Insilico Medicine | United States | In April 2026, Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-based biotechnology organization, announced the strategic formation of the industry’s first Longevity Board. |
Recent Developments in the U.S. AI in Life Science Market
- In November 2026, Axtria Inc., a worldwide leader in AI-first data analytics services for the life sciences industry, announced the launch of its AI-Powered Launch Excellence for Emerging Pharma offering, a transformative service intended to support evolving and mid-sized pharmaceutical organizations in accelerating successful brand launches and achieving commercial excellence.
- In October 2025, Illumina, Inc. announced the launch of BioInsight, a novel business developed by Illumina to meet manufacturing demand for deeper biologic insights driven by the requirement of researchers and pharma organizations to access and interpret ever larger-scale multiomic data.
Market Growth
The U.S. AI in life science market size was estimated at USD 0.95 billion in 2025 and is predicted to increase from USD 1.14 billion in 2026 to approximately USD 5.91 billion by 2035, expanding at a CAGR of 20.05% from 2026 to 2035.
Keypoints
- Company Overview
- Locations Subsidiaries/Geographic reach
- Key Executives
- Company Financials
- Patents registered
- SWOT Analysis
- Applications Catered
- Strategic collaborations
- Recent Developments
- Competitive Benchmarking